CASIF (CASI Pharmaceuticals) PB Ratio: (As of Jul. 06, 2026)


CASIF CASI Pharmaceuticals Inc CASIF
29 GF Score
Price $0.15
GF Value $1.12
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-06), CASI Pharmaceuticals's share price is $0.1469. CASI Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2025 was $-1.81. Hence, CASI Pharmaceuticals's PB Ratio of today is .

The historical rank and industry rank for CASI Pharmaceuticals's PB Ratio or its related term are showing as below:

During the past 13 years, CASI Pharmaceuticals's highest PB Ratio was 75.57. The lowest was 0.34. And the median was 3.86.

CASIF's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.99
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, CASI Pharmaceuticals's average Book Value Per Share Growth Rate was -1624.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CASI Pharmaceuticals was 47.50% per year. The lowest was -73.00% per year. And the median was -21.50% per year.

Back to Basics: PB Ratio


CASI Pharmaceuticals  (OTCPK:CASIF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


CASI Pharmaceuticals PB Ratio Related Terms


CASI Pharmaceuticals PB Ratio Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals PB Ratio Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.32 0.54 3.96 23.78 0.00

CASI Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.78 0.00 0.00 0.00 0.00

CASIF vs ITRMF, OGEN, AZTR: PB Ratio Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's PB Ratio falls into.


CASIF
29GF Score
CASI Pharmaceuticals Inc CASIF
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

CASI Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.1469/-1.814
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of $0.15 is trading 86.9% below its estimated GF Value™ of $1.12. GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CASIF:

  • PB Ratio:
  • GF Value™: $1.12 vs. price of $0.15 (86.9% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CASI Pharmaceuticals Business Description

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for CASIF

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$1.12
GF Value